**Supplementary Materials 2**

**Inclusion criteria**

1. Glycemic control

* Comparative studies on efficacy and safety between the three SGLT2i (empagliflozin, dapagliflozin and luseogliflozin) when given as a combination therapy with other glucose lowering drugs in adult patients with T2DM\*.
* Efficacy outcomes of interest were reduction in HbA1c, fasting plasma glucose level, proportion of patients achieving HbA1c of less than 7% and reduction in body weight while safety outcomes were risk of hypoglycemia, urinary tract infections, genital tract infections, euglycemic ketoacidosis, amputations and bone fracture.

1. Cardiovascular risk reduction

* Studies comparing the efficacy of empagliflozin and dapagliflozin with each other and/or standard of care therapy in adult patients with T2DM\*.
* Outcomes were reduction in risk of major adverse cardiovascular events, cardiovascular death, all-cause mortality and hospitalization due to heart failure.

1. Study design: Randomized controlled trial, meta-analysis, network meta-analysis

\*Non-comparative studies were included if comparative evidence was not available.

**Exclusion criteria**

Observational studies, conference abstracts and non-human studies were excluded.